

ESMO Virtual Congress 2020 Industry Satellite Symposium



Putting personalised healthcare at the heart of clinical practice

Virtual on demand programme

Session title	Speaker
Taking the pulse of personalised healthcare today	Emile Voest
Tracing our path with current tools	Shumei Kato
If tissue is the issue, think blood	Natalie Cook
Learning from real-world patients, in real-life conditions	Kenneth Kehl
Looking at where personalised healthcare has become reality	Emile Voest
Conclusion	Emile Voest

This session will be chaired by Professor Emile Voest

There will be a
virtual live Q&A
with the faculty on
September 18th from
5:00pm - 5:30pm




Speaker Profiles



Prof. Emile Voest

*Professor of Medical Oncology, Medical Director of the NKI
Netherlands Cancer Institute, Amsterdam, NL*

Prof. Voest is a board-certified medical oncologist and translational scientist. In addition to his clinical and managerial responsibilities he heads his own research group. His laboratory work is devoted to bringing personalised medicine to patients.



Prof. Shumei Kato

*Assistant Professor of Medicine
University of California, San Diego (UCSD), San Diego, USA*

Prof. Kato is a board-certified medical oncologist who specialises in treating rare cancers and gastrointestinal tumours. He has a special interest in targeted molecular therapy and his approach to care emphasises personalised medicine and experimental therapeutics.



Dr Natalie Cook

*Senior Clinical Lecturer in Experimental Cancer Medicine and
Honorary Consultant, The Christie NHS Foundation Trust and the
University of Manchester, Manchester, UK*

Dr Cook is a medical oncologist who specialises in the development of early phase clinical trials of experimental anti-cancer therapies, translational assay development and early-phase trials for gastrointestinal cancers medicine to patients.



Dr Kenneth Kehl

*Instructor in Medicine, Harvard Medical School
Physician, Dana-Farber Cancer Institute, Boston, MA, USA*

Dr Kehl is a medical oncologist who focuses on the impact of healthcare delivery strategies on access to care and outcomes for patients with lung cancer, with a particular focus on analysis of population-level data.